Deprescribing antipsychotics in adults with psychotic disorders – a literature review
Mental Health Practice · 04.01.2024 · 27 (1) · 28-33
DOI: 10.7748/mhp.2023.e1670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mental Health Practice, online erschienen am 13.09.2023. Verfasst von Joanna M Painter. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Despite evidence of adverse effects, continuous antipsychotic maintenance treatment is still often the preferred intervention for people with a long-term psychotic disorder. Antipsychotic treatment should be discussed with patients and the option of deprescribing should be explored. There is, however, a lack of guidance on antipsychotic deprescribing as well as a conflict in mental health services between recovery-oriented practice, which promotes collaboration and patient choice, and the more traditional approach of promoting adherence to the clinician’s recommendation. The author conducted a literature review to gather clinical and academic perspectives on antipsychotic deprescribing in adults with a psychotic disorder in the context of recovery-oriented practice. Findings suggest that the adverse effects of long-term antipsychotic use are such that deprescribing should be considered, the challenge for nurses being to find a balance between patient autonomy and risk mitigation.
Zitieren
APA
Painter, J. M. (2024). Deprescribing antipsychotics in adults with psychotic disorders – a literature review. Mental Health Practice, 27(1), 28-33. https://doi.org/10.7748/mhp.2023.e1670
Vancouver
Painter JM. Deprescribing antipsychotics in adults with psychotic disorders – a literature review. Mental Health Practice. 2024;27(1):28-33. doi:10.7748/mhp.2023.e1670
BibTeX
@article{Painter2024,
author = {Painter, Joanna M},
title = {Deprescribing antipsychotics in adults with psychotic disorders – a literature review},
journal = {Mental Health Practice},
year = {2024},
volume = {27},
number = {1},
pages = {28--33},
doi = {10.7748/mhp.2023.e1670}
}
EUVIMED